ABSTRACT

Aim: To determine the efficacy of magnesium sulphate as an anti-convulsant in the management of eclampsia and severe pre-eclampsia. Study design: Comparative, prospective/randomized study Place and duration of study: Department of Obstetrics & Gynaecology, M. Islam Teaching Hospital, Gujranwala from 1st April 2020 to 30th September 2020. Methodology: One hundred and twenty patients were presented in this study with age ranges between 20-40 years. Patients detailed demographics body mass index and gestational age were recorded after taking written consent. The patients who needed magnesium sulphate because of eclampsia or severe pre-eclampsia were included. 4 gm magnesium sulphate was given I/V (intravenous), diluted in 20cc of 5% dextrose, slowly over 15-20 minutes. 5 gm magnesium sulphate I/M was given 4 hourly till 24 hours after delivery or after last convulsion whichever was late. Within 48 hours of magnesium sulphate treatment, seizure was the main outcome. Results: Mean age of the patients was 28.96±4.14 years with mean BMI 26.14±2.43 kg/m2. Sixty seven (55.83%) patients have eclampsia and 53 (44.17%) patients have pre-eclamptics. In 67 patients of eclamptics, fits antenatal 42 (35%), 7 (5.9%) intrapartum and 18 (15%) postpartum were recorded. Twelve (10%) patients of seizures found within 48 hours after treating with magnesium sulphate, 8 (6.7%) in eclamptics and 4 (3.33%) pre-eclamptics. There were 75 (62.5%) women has vaginal deliveries and 45 (37.5%) women have lower segment cesarean sections. 18 (15%) found perinatal deaths while no maternal mortality was found. Conclusion: The minimum use of magnesium sulphate resulted in to control seizures and it has been observed that maternal mortality rate was also decreased. Keywords: Eclampsia, Pre-eclampsia, Magnesium sulphate (MgSO4)